TABLE 2.
Clinical presentation and medications at baseline.
| Characteristics | eGFR ≥ 60 ml/min |
eGFR < 60 ml/min |
||||
| Reduced-bolus (n = 51) | Normal-bolus (n = 51) | P-value | Reduced-bolus (n = 51) | Normal-bolus (n = 51) | P-value | |
| STEMI, no. (%) | 9 (17.6%) | 9 (17.6%) | 1.000 | 7 (13.7%) | 8 (15.7%) | 0.780 |
| NSTE-ACS, no. (%) | 42 (82.4%) | 42 (82.4%) | 1.000 | 44 (86.3%) | 43 (84.3%) | 0.780 |
| Troponin-negative | 29 (56.9%) | 33 (64.7%) | 0.417 | 32 (62.7%) | 37 (72.5%) | 0.290 |
| Troponin-positive | 13 (25.5%) | 9 (17.6%) | 0.336 | 12 (23.55%) | 6 (11.8%) | 0.119 |
| ST-segment deviation | 13 (25.5%) | 9 (17.6%) | 0.336 | 14 (27.5%) | 17 (33.3%) | 0.518 |
| T-wave inversion | 20 (39.2%) | 17 (33.3%) | 0.537 | 23 (45.1%) | 18 (35.3%) | 0.313 |
| Symptom onset to hospital arrival (h) | 96 (24–360) | 168 (24–480) | 0.454 | 240 (72–720) | 360 (168–720) | 0.231 |
| STEMI | 24 (6.5–84) | 11 (6.75–56.5) | 0.478 | 16 (6–192) | 72 (48–240) | 0.221 |
| NSTE-ACS | 168 (42–540) | 204 (90–720) | 0.250 | 288 (84–1,260) | 720 (168–1,440) | 0.251 |
| Killip class II, III, or IV, no. (%) | 3 (5.9%) | 3 (5.9%) | 1.000 | 7 (13.7%) | 7 (13.7%) | 1.000 |
| Previous lytic therapy, no. (%) | 1 (2.0%) | 1 (2.0%) | 1.000 | 1 (2.0%) | 1 (2.0%) | 1.000 |
| Systolic arterial pressure (mmHg) | 136.16 ± 17.28 | 133.33 ± 22.03 | 0.473 | 138.45 ± 22.38 | 138.14 ± 19.96 | 0.941 |
| Heart rate (beats/min) | 78.02 ± 12.79 | 76.18 ± 10.97 | 0.437 | 78.37 ± 13.12 | 78.25 ± 11.09 | 0.961 |
| Cardiopulmonary resuscitation before arrival at the catheterization laboratory, no. (%) | 0 (0.0%) | 2 (3.9%) | 0.475 | 3 (5.9%) | 0 (0.0%) | 0.241 |
| eGFR (ml/min/1.73 m2) | 99.73 ± 25.36 | 100.98 ± 20.92 | 0.785 | 48.97 ± 15.00 | 47.99 ± 10.80 | 0.706 |
| CRUSADE bleeding score a | 21.76 ± 12.17 | 21.45 ± 9.05 | 0.883 | 43.43 ± 11.41 | 42.16 ± 9.21 | 0.536 |
| > 30 (moderate or high bleeding risk), no. (%) | 11 (21.6%) | 7 (13.7%) | 0.299 | 45 (88.2%) | 45 (88.2%) | 1.000 |
| Medications during the hospitalization, no. (%) | ||||||
| Aspirin | 51 (100%) | 51 (100%) | 1.000 | 51 (100%) | 48 (94.1%) | 0.241 |
| Clopidogrel | 41 (80.4%) | 41 (80.4%) | 1.000 | 42 (82.4%) | 46 (90.2%) | 0.250 |
| Ticagrelor | 15 (29.4%) | 16 (31.4%) | 0.830 | 18 (35.3%) | 10 (19.6%) | 0.076 |
| Fondaparinux | 1 (2.0%) | 0 (0.0%) | 1.000 | 3 (5.9%) | 7 (13.7%) | 0.183 |
| Angiotensin-converting enzyme inhibitors | 15 (29.4%) | 20 (39.2%) | 0.297 | 8 (15.7%) | 15 (29.4%) | 0.097 |
| Angiotensin II receptor blockers | 17 (33.3%) | 11 (21.6%) | 0.183 | 34 (66.7%) | 32 (62.7%) | 0.679 |
| Statins | 51 (100%) | 49 (96.1%) | 0.475 | 50 (98.0%) | 51 (100%) | 1.000 |
| Beta-blockers | 35 (68.6%) | 32 (62.7%) | 0.532 | 43 (84.3%) | 37 (72.5%) | 0.149 |
| Calcium channel blocker | 17 (33.3%) | 16 (31.4%) | 0.832 | 32 (62.7%) | 24 (47.1%) | 0.111 |
| Diuretic | 14 (27.5%) | 20 (39.2%) | 0.208 | 30 (58.8%) | 23 (45.1%) | 0.165 |
| Proton-pump inhibitor | 45 (88.2%) | 47 (92.2%) | 0.505 | 46 (90.2%) | 45 (88.2%) | 0.750 |
| Unfractionated heparin | 2 (3.9%) | 2 (3.9%) | 1.000 | 6 (11.8%) | 5 (9.8%) | 0.750 |
| Low molecular weight heparin | 5 (9.8%) | 5 (9.8%) | 1.000 | 8 (15.7%) | 5 (9.8%) | 0.373 |
| Enoxaparin | 34 (66.7%) | 30 (58.8%) | 0.413 | 16 (31.4%) | 18 (35.3%) | 0.674 |
| Rivaroxaban | 0 (0.0%) | 0 (0.0%) | 1.000 | 3 (5.9%) | 3 (5.9%) | 1.000 |
| Bivalirudin | 51 (100%) | 51 (100%) | 1.000 | 51 (100%) | 51 (100%) | 1.000 |
| Glycoprotein IIb/IIIa inhibitor | 6 (11.8%) | 10 (19.6%) | 0.276 | 5 (9.8%) | 4 (7.8%) | 1.000 |
STEMI, ST-segment elevation myocardial infarction; NSTE-ACS, Non-ST-elevation acute coronary syndrome; eGFR, estimated glomerular filtration rate; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines.
aCRUSADE bleeding score denotes the risk of bleeding with higher numbers representing a greater risk of bleeding.